认知健康个体中按阿尔茨海默病生物标志物定义亚组划分的认知与功能随时间变化
研究纳入387名认知未受损个体,按脑脊液、PET和血浆阿尔茨海默病生物标志物分组,随访4.5±3.1年,执行功能任务和延迟词语表再认在各组均显示下降,功能下降除脑脊液和血浆tau阳性组外均可见,随访限制在1.5年或3年时多数效应消失或方向反转。
要点
- 执行功能任务在所有生物标志物组中下降最明显(βtime范围-0.30至-0.71)。
- 延迟词语表再认下降次之(βtime范围-0.18至-0.50)。
- 将随访限制在1.5年或3年时,许多效应消失或方向反转。
核心结论
- 在所有认知域中,功能、复合和神经心理结局指标均能检测不同生物标志物定义组的随时间变化,变化在阿尔茨海默病病理更明显的个体中最明显。
- 作者认为阿尔茨海默病预防试验应使用足够长的随访时间和/或更敏感的结局指标以最佳捕捉细微的认知变化。
研究设计与样本
- 来自阿姆斯特丹痴呆队列和SCIENCe项目的认知未受损个体,基线有脑脊液、PET和血浆阿尔茨海默病生物标志物,随访4.5±3.1年(范围0.6-18.9年)。
- 纳入387人(年龄61.7±8.6岁,44%女性),按常见临床试验入组标准定义部分重叠的生物标志物组:APOE ε4携带者(n=212)、淀粉样蛋白阳性者(n=109)、淀粉样蛋白阳性APOE ε4携带者(n=66)、脑脊液p-tau阳性者(n=127)、血浆p-tau阳性者(n=71)、淀粉样蛋白和脑脊液p-tau均阳性者(n=50),以及生物标志物正常的对照组(n=65)。
- 使用线性混合模型,校正年龄、性别和教育,估计神经心理测试、功能结局和2个认知复合指标随时间的变化,以时间(年)的标准化回归系数(βtime)为感兴趣结局。
- 分析完整随访以及随访限制在1.5年和3年的变化。
主要发现
- 执行功能任务在所有生物标志物组中下降最明显(βtime范围-0.30至-0.71),其次是延迟词语表再认(βtime范围-0.18至-0.50)。
- 功能下降(βtime范围-0.17至-0.63)在所有组中均观察到,但脑脊液和血浆tau阳性组除外。
- 两个复合指标在所有组中显示相当的变化量(βtime范围-0.12至-0.62),但血浆p-tau阳性个体除外。
- 当限制原始随访时间时,许多效应消失或甚至方向反转。
局限性
- 当限制原始随访时间时,许多效应消失或甚至方向反转。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: It is unclear to what extent cognitive outcome measures are sensitive to capture decline in Alzheimer disease (AD) prevention trials. We aimed to analyze the sensitivity to changes over time of a range of neuropsychological tests in several cognitively unimpaired, biomarker-defined patient groups. METHODS: Cognitively unimpaired individuals from the Amsterdam Dementia Cohort and the SCIENCe project with available AD biomarkers, obtained from CSF, PET scans, and plasma at baseline, were followed over time (4.5 ± 3.1 years, range 0.6-18.9 years). Based on common inclusion criteria for clinical trials, we defined groups (amyloid, phosphorylated tau [p-tau], APOE ε4). Linear mixed models, adjusted for age, sex, and education, were used to estimate change over time in neuropsychological tests, a functional outcome, and 2 cognitive composite measures. Standardized regression coefficients of time in years (βtime) were reported as outcome of interest. We analyzed change over time with full follow-up, as well as with follow-up limited to 1.5 and 3 years. RESULTS: We included 387 individuals (aged 61.7 ± 8.6 years; 44% female) in the following (partly overlapping) biomarker groups: APOE ε4 carriers (n = 212), amyloid-positive individuals (n = 109), amyloid-positive APOE ε4 carriers (n = 66), CSF p-tau-positive individuals (n = 127), plasma p-tau-positive individuals (n = 71), and amyloid and CSF p-tau-positive individuals (n = 50), or in a control group (normal biomarkers; n = 65). An executive functioning task showed most decline in all biomarker groups (βtime range -0.30 to -0.71), followed by delayed word list recognition (βtime range -0.18 to -0.50). Functional decline (βtime range -0.17 to -0.63) was observed in all, except the CSF and plasma tau-positive groups. Both composites showed comparable amounts of change (βtime range -0.12 to -0.62) in all groups, except plasma p-tau-positive individuals. When limiting original follow-up duration, many effects disappeared or even flipped direction. DISCUSSION: In conclusion, functional, composite, and neuropsychological outcome measures across all cognitive domains detect changes over time in various biomarker-defined groups, with changes being most evident among individuals with more AD pathology. AD prevention trials should use sufficiently long follow-up duration and/or more sensitive outcome measures to optimally capture subtle cognitive changes over time.
引用
- Dubbelman MA, Hendriksen HMA, Harrison JE, et al. Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups. Neurology. 2023. PMID: 38165338. doi:10.1212/WNL.0000000000207978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。